Stay updated on Lorlatinib in ROS1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Lorlatinib in ROS1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lorlatinib in ROS1+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The site’s footer revision label changed from v3.7.2 to v3.8.0; the study record content appears unchanged.
    Difference
    0.1%
    Check dated 2026-11-01T13:22:13.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    A notice about NIH website changes and the transition from “Artificial Intelligence” to “Super Intelligence” appears above the study record.
    Difference
    0.7%
    Check dated 2026-10-25T13:16:45.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The site revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-18T13:15:10.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-11T14:39:28.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    The history now shows Revision: v3.7.0 as the latest entry, while Revision: v3.6.6 is removed. This reflects an update to the record's revision history.
    Difference
    0.1%
    Check dated 2026-09-20T15:11:28.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    A new latest revision, v3.6.6, is added to the study's Record History. The previous revision, v3.6.5, is removed from the current list, reflecting an update to the record.
    Difference
    0.1%
    Check dated 2026-08-29T23:46:26.000Z thumbnail image

Stay in the know with updates to Lorlatinib in ROS1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lorlatinib in ROS1+ NSCLC Clinical Trial page.